Generation and characterization of a unique reagent that recognizes a panel of recombinant human monoclonal antibody therapeutics in the presence of endogenous human IgG.
Wang, X., Quarmby, V., Ng, C., Chuntharapai, A., Shek, T., Eigenbrot, C., Kelley, R.F., Shia, S., McCutcheon, K., Lowe, J., Leddy, C., Coachman, K., Cain, G., Chu, F., Hotzel, I., Maia, M., Wakshull, E., Yang, J.(2013) MAbs 5: 540-554
- PubMed: 23774668 
- DOI: 10.4161/mabs.24822
- Primary Citation of Related Structures:  
4K7P - PubMed Abstract: 
Pharmacokinetic (PK) and immunohistochemistry (IHC) assays are essential to the evaluation of the safety and efficacy of therapeutic monoclonal antibodies (mAb) during drug development. These methods require reagents with a high degree of specificity because low concentrations of therapeutic antibody need to be detected in samples containing high concentrations of endogenous human immunoglobulins ...